Topics

Corrigendum. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.

08:00 EDT 11th June 2019 | BioPortfolio

Summary of "Corrigendum. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: Human reproduction (Oxford, England)
ISSN: 1460-2350
Pages:

Links

DeepDyve research library

PubMed Articles [20657 Associated PubMed Articles listed on BioPortfolio]

Bleeding and spotting with the levonorgestrel 13.5mg intrauterine system: the impact of insertion timing.

To assess the impact of early versus late menstrual cycle insertion on bleeding/spotting in the 90days following levonorgestrel (LNG) 13.5mg intrauterine system (IUS) insertion.

Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system.

To determine the long-term effects of using the levonorgestrel-releasing intrauterine system (LNG-IUS) to treat symptomatic adenomyosis.

Case report of the successful use of Mirena levonorgestrel intrauterine system in a patient with didelphys uterus and obstructed hemivagina.

The Mirena levonorgestrel intrauterine system (IUS) is frequently used for menstrual suppression in adolescents with special needs. However, the presence of a uterine anomaly is generally considered a...

A prospective cohort study comparing expulsion after post-placental insertion: the levonorgestrel versus the copper intrauterine device.

To compare the expulsion rate at 6months after post-placental insertion by intrauterine device type.

Two Cases of Acute Cholecystitis and Symptomatic Choledocholithiasis in Two Women Less than 40-Years-of-Age with Hormonal Intrauterine Devices.

Levonorgestrel uterine implants are accepted as a safe and efficacious method of contraception. One of the two major health side effects in a large controlled study of subcutaneous hormonal implants w...

Clinical Trials [4850 Associated Clinical Trials listed on BioPortfolio]

Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion

The study is a randomized controlled trial comparing outcomes of immediate postplacental insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) vs. interval insertion of t...

Pretreatment With Mifepristone Prior to Mirena Insertion

Hypothesis: Pretreatment with mifeprsitone prior to Mirena placement will induce amenorrhea and reduce bleeding irrregularities during the initial months of Mirena use.

Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device (IUD) After Vaginal Delivery

This study is a randomized controlled trial comparing 6 month usage rates of the levonorgestrel-releasing intrauterine device (LNG-IUD) when inserted postplacentally after vaginal delivery...

Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis

Randomized clinical trial the use of levonorgestrel releasing intrauterine system. Objectives: To evaluate and compare the efficacy of- levonorgestrel releasing intrauterine system l(LNG-...

The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding

Research hypothesis: Release of levonorgestrel from Metraplant-E levonorgestrel releasing intrauterine contraceptive device is inadequate to be used as a medical line of treatment of dys...

Medical and Biotech [MESH] Definitions

A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.

Spontaneous loss of INTRAUTERINE DEVICES from the UTERUS.

Cell surface proteins that bind corticotropin-releasing hormone with high affinity and trigger intracellular changes which influence the behavior of cells. The corticotropin releasing-hormone receptors on anterior pituitary cells mediate the stimulation of corticotropin release by hypothalamic corticotropin releasing factor. The physiological consequence of activating corticotropin-releasing hormone receptors on central neurons is not well understood.

The shifting in position or location of an INTRAUTERINE DEVICE from its original placement.

Intrauterine devices that release contraceptive agents.

Quick Search


DeepDyve research library

Searches Linking to this Article